Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFKB, STAT and API transcription factor families by Boulukos, Kim E. et al.
Histol Histopathol (2001) 16: 595-601 
http://www.ehu.es/histol-histopathol 
Histology and 
Histopathology 
Cellular and Molecular Biology 
Revie w 
Transcriptional regulation of the bcl-x gene encoding the 
anti-apoptotic Bcl-xL protein by Ets, R~IINFKB, STAT and 
API transcription factor families 
L. Sevilla, A. Zaldumbide, P. Pognonec and K.E. Boulukos 
lnstitute of Signalisation, Developmental Biology and Cancer, Centre de Biochimie, 
Université de Nice, Faculté des Sciences, Nice, France 
Summary. Transcription factors play an essential role in 
determining the fate of a cell by affecting the expression 
of target genes involved in proliferation, in 
differentiation and in programmed cell death. Under 
certain conditions, some of these factors are capable of 
deregulating expression of genes involved in the cell 
cycle andlor in programmed cell death resulting in 
uncontrolled proliferation of the cell. The focus of this 
review is on the transcriptional regulation of the bcl-x 
gene encoding the anti-apoptotic Bcl-xL protein. Since 
1999, severa1 papers have implicated members of the 
Ets, R~~/NFKB, S T N  and AP-1 families as transcription 
factors regulating bcl-x expression. A specific emphasis 
of these different transcription factor families on bcl-x 
regulation in hematopoietic cells is discussed. 
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lntroduction 
Programmed cell death by apoptosis is a process 
essential for normal development and maintenance of 
cell homeostasis in organisms. Proteins of the bcl-2 
family have been identified as initiators or inhibitors of 
apoptosis. The balance in the levels of expression of pro- 
apoptotic versus anti-apoptotic members is crucial in 
determining the fate of a cell: a more abundant 
expression of an anti-apoptotic member will permit a 
cell to survive whereas a higher expression of a pro- 
apoptotic member will induce apoptosis upon activation 
by a variety of apoptotic signals. 
Anti-apoptotic members include Bcl-2, Bcl-xL 
(Boise et al., 1993), Bcl-w (Gibson et al., 1996), A l  (Lin 
et al., 1996) and Mcl-1 (Kozopas et al., 1993). Bcl-2, the 
first anti-apoptotic member identified, and the closely 
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related Bcl-xL are probably the best characterized. Their 
genomic structures are similar and are believed to have 
arisen from a common ancestral gene or by gene 
duplication (Grillot et al., 1997). By maintaining the 
integrity of mitochondria, Bcl-2 and Bcl-,L inhibit 
cleavage-mediated activation of the caspase cascade 
which functions as the ultimate downstream effector 
pathway of the suicide program degrading proteins 
necessary for nuclear and cell integrity. Until recently, 
little was known about how these genes are regulated. In 
this review, we will focus on the transcriptional 
regulation of one member of the anti-apoptotic family, 
Bcl-xL 
The bcl-x gene encodes severa1 altematively spliced 
messenger RNAs including bcl-xL, bcl-x,, bclATM and 
bcl-fi (Shiraiwa et al., 1996; Grillot et al., 1997). Bcl-xL 
suppresses whereas Bcl-x induces apoptosis (Boise et 
al., 1993; Fang et al., 1694; Gonzalez-Garcia et al., 
1994). The functions of the other two transcripts have 
not yet been well documented. Bcl-xL is believed to be 
the key anti-apoptotic protein expressed in 
hematopoietic lineages including myeloid precursors and 
macrophages (Lotem and Sachs, 1995; Chatterjee et al., 
1997; Packham et al., 1998; Sevilla et al., 1999), 
lymphoid cells of the pre-B lineage (Fang et al., 1994; 
Grillot et al., 1996), and double positive CD4+/CD8+ T 
cells (Grillot et al., 1995; Ma et al., 1995). Bcl-xL 
expression is activated in B cells of the germina1 center 
and in mature resting B and T lymphocytes after 
activation with mitogens and costimulatory signals 
(Broome et al., 1995; Grillot et al., 1996). Interestingly, 
pro-apoptotic Bcl-x is not detected in murine T or 
myeloid cells (~onzafez-~arcia et al., 1994; Packharn et 
al., 1998; Sevilla et al., 1999). The importante of Bcl-xL 
in hematopoiesis has been confirmed by bcl-x gene 
disruption studies in mice which die at E12-13 of 
embryonic development due to massive neurona1 and 
hematopoietic progenitor apoptosis (Motoyama et al., 
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1995). Bcl-xL expression has been shown to be activated 
by retroviral insertions in murine myeloid and T cell 
hematopoietic malignancies demonstrating that the 
expression of Bcl-xL can also be altered in cancer 
(Packham et al., 1998). 
The bcl-xL transcript is upregulated in hematopoietic 
cells upon a variety of stimuli. Among these are stimuli 
including interleukin-2 (IL-2), IL-3, IL-6, granulocyte 
macrophage colony stimulating factor (GM-CSF), 
colony stimulating factor (CSF-l), leukemia inhibitory 
factor (LIF), and erythropoietin (Epo) which induce the 
survival andlor proliferation of hematopoietic cells. bcl-x 
has been shown to be an immediate early gene in Epo- 
treated HCD57 erythroleukemia cells (Socolovsky et al., 
1999) whereas in myeloid cells, bcl-x was shown to be a 
delayed early gene whose transcriptional activation is 
dependent on de novo protein synthesis after CSF-1 
(Sevilla et al., 1999) or IL-3 (Packham et al., 1998) 
stimulation. In addition to the bcl-xL transcript having a 
relatively short half life (Sevilla et al., 1999), the 
expression of the Bcl-xL protein parallels that of the bcl- 
xL transcript (Packham et al., 1998). It was therefore 
important to clone and characterize the bcl-x promoter to 
gain insight as  to how bcl-x is  regulated at the 
transcriptional leve1 upon these different cytokine or 
growth factor signals. 
The human and murine bcl-x promoters have been 
isolated and two distinct regions of the mouse bcl-x gene 
have been shown to have promoter activity (Grillot et 
al., 1997). The first promoter region of 57 bp is found 
immediately upstream of the first coding exon (exon 11) 
and the second promoter region is upstream of the first 
non-coding exon (exon 1). Major transcription initiation 
sites have been mapped to both regions. The differences 
in promoter usage may be attributed to a specific cell 
type or to the status of differentiation of the cell, 
although this remains to be determined. Sequence 
comparisons between the human and mouse promoters 
permitted the identification of highly conserved 
consensus binding sites for different transcription 
families (Grillot et al., 1997). The objective of this report 
is to review the different families of transcription factors 
which have been shown to activate the bcl-x promoter. 
Ets 
The Ets family of transcription factors consists of 
approximately 30 members al1 possessing a conserved 
DNA binding domain of about 85 amino acids known as 
the "E" or "Ets" domain [(Boulukos et al., 1989); 
reviewed in (Ghysdael and Boureux, 1997)l. Etsl, the 
progenitor to v-Ets found in the E26 retrovims, and Ets2 
are 97% conserved in the Ets domain (Boulukos et al., 
1988), whereas PU.1lSpi.l is highly divergent in this 
domain [37% identity; (Wasylyk et al., 1993)l. These 
differences in sequence identity of the Ets domain allow 
Etsl, Ets2 and PU.1lSpi.l to bind to comrnon as well as 
distinct optimal DNA target sequences known as Ets 
binding sites (EBS). 
In addition to their roles in proliferative and 
differentiation pathways, severa1 studies suggested that 
ets family members might affect the survival of cells. 
Apoptosis was observed in etsl-deficient T cells from 
chimeric mice generated by e t s l  gene disruption in 
embryonic stem cells with RAG2-1- blastocysts using the 
recombination activating gene complementation assay 
(Bories et al., 1995; Muthusamy et al., 1995). In other 
studies, Jin et al., reported that primary peritoneal 
macrophages obtained from "dominant negative" Aets2 
transgenic animals died rapidly by apoptosis when 
depleted of CSF-1 (Jin et al., 1995), a factor necessary 
for the growth, differentiation and survival of myeloid 
cells. Finally, other experiments using PU.11 Spi.1, 
showed that PU.11 Spi.1 cooperated with an activated 
erythropoietin receptor (EpoR) to inhibit apoptosis in 
primary erythroblasts (Tran Quang et al., 1997). Taken 
together, these observations suggested that the role in 
inhibiting programmmed cell death may be a common 
function of members of the ets  family, yet the 
mechanism(s) of this inhibition have not been elucidated 
in these studies. 
Like Bcl-xL, PU.1lSpi.l  is expressed in 
hematopoietic precursors and in mature macrophages 
and pu.1-1- mice are devoid of mature B cells,  
neutrophils or  macrophages (Scott et al., 1994; 
McKercher et al., 1996). Etsl and E t B  are specifically 
and reciprocally expressed during precise stages of 
thymic development (Pognonec et al., 1987, 1988; Bhat 
et al., 1989, 1990). Bcl-2 and Bcl-xL are also expressed 
in a reciprocal manner during T cell development and 
interestingly, Ets2 and Bcl-xL are coexpressed in the 
same population of developing T cells. Coexpression of 
Ets2 and Bcl-xL is not limited to double-positive 
CD4+/CD8+ T cells since both are also coexpressed in 
primary bone marrow macrophages (BMM) derived 
from bone marrow progenitor cells and in BMM upon 
activation of functional competence signals (Sevilla et 
al., submitted). 
Transient expression of Ets2 in human 293 cells 
upregulates Bcl-xL protein expression (Sevilla et al., 
1999). Constitutive expression of Ets2 in a CSF-1- 
dependent macrophage cell line (BAC1.2F5) also 
upregulates Bcl-xL expression in a constitutive manner 
and renders these cells resistent to apoptosis when 
depleted of CSF-1 (Sevilla et al., 1999). The most 
plausible mechanism of upregulation of Bcl-xL by Ets2 
was by transcriptional activation. 
Both the 5' regulatory sequences found upstream of 
the first noncoding exon of bcl-x and the first facultative 
intron contain potential EBS for Ets transcription factors. 
Eight EBS are found within a 700 bp fragment of the 
human promoter upstream of the first non-coding exon 
and one in the first intron (Fig. l ) ,  while the predicted 
number of EBS found in a random 700 bp sequence is 
1.07. The  conservation of the human and mouse 
promoter regions is over 70% (Grillot et al., 1997). Like 
the human bcl-x promoter, the murine bcl-x promoter 
also contains a high concentration of sites (11 EBS in 
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700 bp). Ets2, but also Etsl and more distantly related 
PU.1, al1 individually transcriptionaliy activate the bcl-x 
promoter with similar capacities (Sevilla et al., 1999). 
Deletions of dista1 sites show that maximal activity 
requires the integrity of these sites (Sevilla et al., 1999). 
Together, these results show that different members of 
the ets family play a role in inhibiting programmmed 
cell death and at least one mechanism of inhibition by 
Ets transcription factors is by regulation of expression of 
the bcl-x gene. 
RelINF-KB transcription factors are homo- and 
heterodimeric proteins consisting of related subunits. 
R~~/NF-KB transcription factors rapidly translocate to 
the nucleus upon growth factor, cytokine, vira1 or stress 
stimuli and regulate the expression of many genes 
important for the function of the immune system (Hatada 
et al., 2000). Members include p50 ( N F K B ~ ) ,  p52 
(NFKB~), p65 (RelA), c-Rel, the progenitor to v-Re1 of 
the Rev-T avian retrovirus, and RelB [for review see 
(MacKichan and Israel, 1997)l. 
Gene disruption studies in mice have demonstrated 
that RelINFKB transcription factors are critica1 in 
regulating genes induced during immune responses [see 
(Grossmann et al., 1999)l. Severa1 in vivo studies 
suggested that Rel/NFKB played a role in the inhibition 
of apoptosis since inactivation of RelA/p65 in re&-/- 
mice leads to embryonic death due to massive apoptosis 
of the liver (Beg et al., 1995). Double knock-out c-rel-l- 
relA-1- mice die earlier in utero than relA-1- from 
increased apoptosis of the liver, and hematopoietic 
progenitors recovered from c-rel-/-re&-/- fetal livers fail 
to support survival of lethally irradiated mice 
(Grossmann et al., 1999). These results demonstrate that 
both c-Re1 and RelA have overlapping functions and 
regulate the survival of committed hematopoietic 
progenitors. 
Many genes implicated in inducing or inhibiting 
apoptosis contain NFKB-like elements in their promoter 
regions [see Tables in (Dixon et al., 1997; Chen et al., 
1999)l. Four recent studies show that RelINFKB is 
important in the regulation of Bcl-x expression in cells. 
Tan, a regulatory protein encoded ky fhe human T-cell 
leukemia virus type 1, renders the C m 2  mouse T cell 
line IL-Zindependent (Iwanaga et al., 1999). This first 
study showed that the loss of IL-2 dependence and 
resistance to apoptosis of these cells correlate with an 
increase of Bcl-xL expression induced by Tax through a 
NFKB pathway (Tsukahara et al., 1999). CD40, a 
member of the tumor necrosis factor receptor family, 
induces survival of B cells. In another study, Lee et al., 
showed that NFKB upregulated Bcl-xL expression and 
that this upregulation is required for CD40 survival 
signals in hunxm- Daudi and Ramos B cell lines (Lee et 
al., 1999).  In otti'er studies, using human HT1081 
fibrosarcoma cells and HeLa cells expressing inducible 
Re1 proteins, Chen et al., showed that both c-Re1 and 
RelAlp65 increase Bcl-xL expression (Chen et al., 
2000). Finally, macrophages from p50-1- mice have 
increased Bcl-xL levels and are more resistent to silica- 
induced cell death (Chen et al., 1999). Silica was shown 
to activate p50/p50 N F K B ~  homodimers in macrophages 
obtained from wildtype mice and to induce apoptosis, 
whereas silica activates p65-containing complexes in 
macrophages from p50-1- mice (Chen et al., 1999). 
%o NFKB-like sites are found in the 700 bp bcl-x 
promoter sequence (Fig. 1). Although p65/RelA, 
pSO/NFkBl, RelB and c-Re1 al1 bind to these NFkB-like 
elements (Chen et al., 1999, 2000; Lee et al., 1999; 
Tsukahara et al., 1999), only c-Re1 and p65 were shown 
to transactivate the bcl-x promoter in hematopoietic cells 
(Chen et al., 1999; Lee et al., 1999; Chen et al., 2000). 
u NE kappaB Binding Site 
m STAT Bindllig Site 
Flg. 1. The structure of the S regulatory sequences of the human bcl-x gene. Binding sites for Ets, RelINF-KB, STAT and AP-1 transcription factor 
families were determined using the Matlnspector program (Quandt et al., 1995). Conserved consensus motifs, TATA box, exons, and a major 
transcription initiation site (+1) are indicated in the figure. 
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These results show that R~~INFKB,  another important 
transcription factor family, plays a role in the regulation 
of bcl-x expression specifically in B and T cells. 
R~VNFKB can also function as a negative regulator of 
Bcl-xL in double-positive CD4+/CD8+ thymocytes 
(Hettmann et al., 1999). Therefore, additional 
experirnents are needed to clarify under what conditions 
R ~ ~ I N F K B  functions as a positive regulator or as a 
negative regulator of bcl-x expression. 
STA Ts 
Signal Transducers and Activators of Transcription 
(STATs) play key roles in growth factor, cytokine or 
hormone-mediated intracellular signal transduction. 
Ligand binding initiates phosphorylation of tyrosine 
residues and subsequent homo- or heterodimerization of 
the STAT proteins. This phosphorylation activates 
STATs to migrate from the cytoplasm into the nucleus, to 
bind to specific DNA sequences in the promoter regions 
of certain genes and to activate or repress the 
transcription of these target genes. Seven members of the 
STAT family as well as four isoforms lacking their 
variable transactivation domains have been identified. 
It was first reported that Bcl-xL proteins are 
regulated by the Jak kinase pathway independent of 
STATs in hematopoietic cells (Packham et al., 1998). 
This conclusion was based on experiments using the 
mouse immortalized myeloid progenitor 32D.3 cell line 
expressing different EpoR mutants treated with Epo. 
However, more recent studies from several laboratories 
indicate that STATs do effect Bcl-x expression. 
Embryos from stat5a-1- stat5b-1- double k ockout mice 
show severe defects in fetal liver erythroid progenitors 
and that these erythroid progenitors undergo increased 
apoptosis in vitro (Socolovsky et al., 1999). stat5a-l- 
stat5b-1- erythroid progenitors are less responsive to Epo 
(Socolovsky et al., 1999), a cytokine essential for their 
growth and survival, and Epo activation of STAT5 in 
Epo-dependent HCD57 erythroleukemia cells mediates 
the induction of Bcl-x through direct binding of STAT5 
to the bcl-x prometer ?silva et al., 1999). Only STATS, 
and not STATl or STAT3, bind to the bcl-x promoter in 
response to Epo in these cells (Silva et al., 1999). 
The regulation of bcl-x transcription by STAT5 is not 
limited to erythroid cells. The mouse pro-B BaF3 cell 
line is dependent on IL-3 for its growth and survival. 
BalF3 cells expressing a constitutively active STAT5 
mutant rendered these ceiis iL-3 independent and Bcl-xL 
mRNA expression was upregulated (Nosaka et al., 
1999). A complementary approach using a "dominant 
negative" mutant of STM5a in Ba/F3 ceiis showed that 
Bcl-xL was downregulated and IL-3 removal rendered 
these cells more sensitive to apoptosis (Dumon et al., 
1999). These authors went further to demonstrate that 
STAT5 transcriptionally activated the bcl-x promoter in 
Ba/F3 cells (Dumon et al., 1999). 
Other members of the STAT family may be 
implicated in the transcriptional regulation of the bcl-x 
gene and this regulation may occur in nonhematopoietic 
cell types as well. Supporting this notion are studies 
showing that STAT1, but not STAT3, mediates the 
expression of the bcl-x gene upon LIF treatment of 
cardiac myoblasts (Fujio et al., 1997). 
AP1 wmplexes 
c-Fos and c-Jun, the progenitors of their oncogenic 
counterparts in murine osteosarcoma viruses FBJ.MuSV 
and FBR.MuSV, and in a chicken osteosarcoma ASV17, 
respectively, are immediate early genes which are 
rapidly activated in response to a wide variety of 
extracellular stimuli. The fos family consists of c-Fos, 
Fra-1, Fra-2 and FosB and the jun family consists of c- 
Jun, JunB and JunD. Both Fos and Jun are members of 
the basiclleucine zipper family. Jun proteins can form 
homodimers but Fos proteins cannot homodimerize. 
However, Fos proteins can heterodimerize with Jun 
proteins and regulate the transcription of target genes 
whose promoters contain AP1 DNA binding sites. Jun 
homodimers or Fos/Jun heterodimers are also known as 
the AP1 complex. Although the expression of Fos and 
Jun members is often transient, their AP1 activity have 
been shown to profoundly effect both proliferation and 
differentiation pathways [for review see (Bannister and 
Kouzarides, 1997)l. 
More recently, AP1 activity has been implicated as 
being potentially important in regulating anti-apoptotic 
genes (Jacobs-Helber et al., 1998). When c J u n  was 
present in the AP1 complex of Epo-treated HCD57 
erythroid cells, these cells survived. However, Epo 
withdrawal led to the presence of JunB in the AP1 
complex and JunB activity correlated with increased 
death. A dominant negative mutant of cJun inhibited the 
downregulation of Bcl-xL expression and rendered 
HCD57 cells resistant to cell death after Epo depletion 
(Jacobs-Helber et al., 1998). Characterization of the bcl- 
x promoter revealed the presence of an AP1 site 
upstream of the first non-coding exon (Fig. 1) and that c- 
Fos and cJun were shown to transactivate the bcl-x gene 
via this AP1 site (Sevilla et al., 1999). 
Cooperation of different transcription factor families 
in regulatlng bcl-x gene expression 
The activation of Ets, ReVNF-KB, STATs and AP-1 
transcription factors after stimulation with a variety of 
extracellular signalling molecules in different 
hematopoietic lineages clearly correlates with the 
increased expression of Bcl-xL. Since members of these 
different families are rapidly activated upon many of the 
same stimuli and in the same cell types, severa1 
questions remain: is there cooperation between the 
different classes of transcription factors in bcl-x gene 
regulation and if so, what are these factors and under 
which conditions do they cooperate? To begin to address 
these questions, recent studies from our laboratory have 
investigated the effects on the coexpression of members 
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of the different transcription factor families on bcl-x 
regulation. 
The protein of reference in these studies was Ets2. 
When STATSa was activated in the presence of Ets2, 
STATS actually diminished the capacity of Ets2 to 
transactivate (Sevilla et al., 2001). Either STATSa was 
physically interfering with the capacity of Ets2 to bind to 
EBS, or STATSa was sequestering an unidentified 
cofactor from Ets2. A potential cofactor may be a 
protein of the p300lCreb-binding protein (CBP) family 
which interacts with both STATS (Pfitzner et al., 1998) 
and Ets2 (Jayaraman et al., 1999) (see below). 
Coexpression of c-Fos and cJun with Ets2, resulted 
in an increase in transactivation, but this effect was only 
additive (Sevilla et al., 2001). Many promoters contain 
AP-11Ets binding sites and cooperation between the AP1 
complex and Ets is well documented [for review see 
(Bannister and Kouzarides, 1997) and references 
therein]. The basic region of cJun has been shown to 
physically interact with the DNA binding domain of 
severa1 members of the ets family including Etsl, Ets2 
and PU.l (Bassuk and Leiden, 1995; Basuyaux et al., 
1997). Yet the significance of APlIEts activity on the 
bcl-x promoter needs further attention. 
ReVNF-KB and c-Fos and cJun are often activated 
in parallel in the same cell type upon the same stimulus. 
For example, as seen in this review Rel/NF-KB and c- 
Fos and cJun are al1 activated in Epo-treated HCD57 
cells. It appears that via their leucine zippers, c-Foslc- 
Jun interact with the re1 homology domain of Rel/NF-KB 
and stimulate RelJNF-KB DNA binding (Stein et al., 
1993). ReUNF-KB members have also been shown to 
collaborate with AP1 and Ets on the GM-CSF promoter 
in human Jurkat T cells (Thomas et al., 1997). Whether 
these interactions occur or not on the bcl-x promoter 
after Epo stimulation of erythroid cells or after 
stimulation of other cell types has not yet been 
established. 
Surprisingly, coexpression of two members of the ets 
farnily, PU.1 and Ets2, resulted in a clear synergy on the 
bcl-x promoter (Sevilla et al., 2001). This synergy of 
Ets2 and PU.l was specific since coexpression of Etsl 
with either Ets2 or with PU.l had no effect on bcl-x 
activity. Since Etsl is not expressed in macrophages, 
whereas Ets2 and PU.l proteins are, the regulation of the 
bcl-x promoter at the molecular level parallels biological 
expression. Both PU.l and Ets2 transactivation domains 
are required for this synergy and the integrity of the bcl- 
x promoter is necessary for maximal synergy between 
Ets2 and PU.1 since deletions of 2 or more sites greatly 
reduced the synergistic capacity of these two 
transcription factors. Interestingly, PU.l and Ets2 
proteins are known to bind to DNA as monomers 
[reviewed in (Ghysdael and Boureux, 1997)l and do not 
physically interact (personal observations). Either these 
proteins do not directly interact or their interactions are 
weak andlor transient. It is possible that these proteins 
interact via a third bridging factor. Proteins of the 
p300lCBP family are coactivators of transcription 
binding to transcription factors and affecting their 
transcriptional capacities, and are known to have histone 
acetyltransferase functions capable of modulating 
chromatin structure. Recently, p300lCBP have been 
identified as proteins interacting with PU.l (Yamamoto 
et al., 1999) or Ets2 (Jayaraman et al., 1999). 
Preliminary experiments suggest that PU.l, Ets2 and 
p300lCBP physically interact and cotransfections of 
HeLa cells with p300lCBP greatly increased the 
activities of Ets2 and PU.l on the bcl-x promoter. 
Therefore p300lCBP appears be a ternary factor 
involved in Ets2IPU.1 synergistic activity on the bcl-x 
promoter (Zaldumide et al, in prep.). 
The Bcl-x protein plays an important role in 
maintaining tke integrity of mitochondria thereby 
inhibiting the release of factors which activate the pro- 
apoptotic caspase cascade. The level of protein 
expression parallels that of its mRNA transcript and it is 
well established that high Bcl-xL expression correlates 
with high cell survival in cells subjected to apoptotic 
signals. bcl-x is regulated at the transcriptional level 
upon activation of cells with a variety of stimuli 
including survival/growth factors. Recent studies from 
severa1 laboratories have characterized severa1 
transcription factor families involved in regulating the 
bcl-x gene. Members of the Ets, ReVNF-KB, STAT and 
AP-1 families of transcription factors have al1 been 
implicated in this regulation in hematopoietic cells. 
Although some of these transcription factor families 
activate bcl-x transcription in an additive or synergistic 
fashion, further studies will be needed to determine 
under which circumstances and in what celi types these 
transcription factors function together to regulate bcl-x 
gene expression. 
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